10.1155/2020/8840675 Neural Plast
The federal court has set up a single Multidistrict Litigation, or MDL 3094: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation, where the court will hear claims regarding injuries caused by Ozempic, Wegovy, Mounjaro, Trulicity and Reybelsus
Protein-first approach: Minimum 0.7-1.0g protein per pound of body weight daily
Other Ingredients: Glycerin, Purified Water, Citrus Oil and Vanilla (Natural Flavors), Beta Carotene (Natural Color), Potassium Bicarbonate, Less than 1%: Oleic Acid, and Citric Acid
The market is expanding at a CAGR of 28.54% between 2025 and 2034
Originally approved under the brand name Mounjaro for Type 2 diabetes management, Tirzepatide has since been approved under Zepbound for chronic weight management in adults